Please Wait.....
Report
Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others), By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others), By Region and Competition, 2020-2030F
Market Report I 2025-08-25 I 185 Pages I TechSci Research
Market Overview
Global Cancer Gene Therapy Market was valued at USD 4.52 billion in 2024 and is expected to reach USD 13.58 billion by 2030 with a CAGR of 20.12% during the forecast period. The global market for Cancer Gene Therapy is experiencing significant growth, driven by the growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increase the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about advantages of using gene therapy and diagnosis along with increasing healthcare expenditure on cancer treatment across the globe is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States. Cancer is one of the deadliest diseases in the world, and it has been a significant concern for public health for decades.
Key Market Drivers
Rising Global Cancer Burden and Need for Precision Therapies
The rising global burden of cancer is a fundamental driver of the cancer gene therapy market. According to the World Health Organization (WHO), cancer is a leading cause of death globally, responsible for nearly 10 million deaths in 2020. The most common forms include lung, breast, colorectal, prostate, and stomach cancer. Traditional treatments like chemotherapy and radiation often have systemic toxicity and variable efficacy, particularly in advanced-stage or genetically complex tumors. Gene therapy offers a transformative approach to cancer treatment by directly targeting the genetic root of disease-whether through inserting therapeutic genes, editing faulty ones, or using viral vectors to trigger immune responses. This is especially critical in cancers where oncogenic mutations drive resistance to conventional therapies.
The U.S. National Cancer Institute (NCI) and similar institutions in Europe and Asia are significantly increasing funding for precision medicine and gene-based oncology research. In the U.S., the 21st Century Cures Act and initiatives like the Cancer Moonshot have allocated billions toward advanced cancer research, including gene therapy. As the prevalence of cancer continues to climb due to aging populations and environmental exposures, the demand for targeted and durable treatments like gene therapy is expected to rise. These therapies not only promise improved survival outcomes but also offer the potential for long-term remission or even cures, particularly in genetically defined cancers like hematological malignancies or glioblastomas.
Key Market Challenges
High Cost and Limited Access to Gene Therapy
One of the primary challenges facing the global cancer gene therapy market is the high cost of treatment and the resultant limited patient access, particularly in low- and middle-income countries. Gene therapy, especially when customized for individuals, requires sophisticated manufacturing processes, skilled personnel, and stringent regulatory compliance, all of which contribute to its premium price. Approved therapies like CAR-T treatments have been priced between $350,000 to $500,000 per patient in markets like the U.S. and Europe. This cost does not account for hospitalization, supportive care, or follow-up, making the overall financial burden even higher. These prices place a significant strain on healthcare systems, especially those that operate on public insurance or low reimbursement thresholds.
Government health agencies, including the U.S. Centers for Medicare & Medicaid Services (CMS), have explored reimbursement models like outcomes-based pricing to make these therapies more sustainable. However, in many parts of Asia, Africa, and Latin America, such policies are either underdeveloped or non-existent, preventing wider adoption of gene therapy innovations. The affordability issue becomes more complex when considering the need for lifelong monitoring and potential retreatment. As gene therapies are still in the early stage of commercialization, cost reduction through economies of scale has not yet materialized. Until these therapies become more economically viable and globally accessible, their impact on global cancer care will remain uneven.
Key Market Trends
Expansion of Personalized Cancer Gene Therapy
A major trend in the global cancer gene therapy market is the movement toward highly personalized medicine. Advances in genomics and next-generation sequencing (NGS) have enabled detailed characterization of cancer at the molecular level, identifying specific genetic mutations, epigenetic modifications, and biomarkers. This data is being used to tailor gene therapies uniquely suited to individual patients' tumor profiles. For instance, gene-editing platforms like CRISPR-Cas9 are now being explored to create bespoke cancer therapies, where genes are selectively silenced or corrected. Similarly, personalized CAR-T cell therapies-where a patient's T-cells are genetically modified to recognize tumor-specific antigens-have already shown success in treating refractory blood cancers like leukemia and lymphoma.
Global governments are actively investing in precision oncology. For example, the U.K. has launched the Genomic Medicine Service within the NHS, integrating whole genome sequencing into cancer diagnosis and treatment planning. In the United States, the Precision Medicine Initiative supports integrating molecular data into clinical care, including gene therapy applications. This trend signifies a shift from the "one-size-fits-all" treatment paradigm to customized interventions with potentially fewer side effects and higher therapeutic success. As genomic profiling becomes more accessible, the scope for personalized gene therapy will continue to expand, reshaping the way cancer is treated across various demographics and geographies.
Key Market Players
- Abeona Therapeutics Inc.
- Asklepios BioPharmaceutical Inc.
- Altor Bioscience Inc.
- BioCancell Inc.
- Celgene Inc.
- Elevate Bio Inc.
- Genelux Corporation
- Introgen Therapeutics Inc.
- OncoGenex Pharmaceuticals Inc.
- Merck KGaA
Report Scope:
In this report, the Global Cancer Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Cancer Gene Therapy Market, By Therapy:
o Oncolytic Virotherapy
o Gene Induced Immunotherapy
o Gene Transfer
o Others
- Cancer Gene Therapy Market, By Indication:
o Breast Cancer
o Ovarian Cancer
o Lung Cancer
o Liver Cancer
o Pancreatic Cancer
o Prostate Cancer
o Others
- Cancer Gene Therapy Market, By End User:
o Biotechnology & Pharmaceutical Companies
o Academic & Research Institutions
o Others
- Cancer Gene Therapy Market, By Region:
o North America
United States
Mexico
Canada
o Europe
France
Germany
United Kingdom
Italy
Spain
o Asia-Pacific
China
India
South Korea
Japan
Australia
o South America
Brazil
Argentina
Colombia
o Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Cancer Gene Therapy Market.
Available Customizations:
Global Cancer Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Cancer Gene Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
7. North America Cancer Gene Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Indication
7.2.3. By End User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Cancer Gene Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Indication
7.3.1.2.3. By End User
7.3.2. Canada Cancer Gene Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Indication
7.3.2.2.3. By End User
7.3.3. Mexico Cancer Gene Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By Indication
7.3.3.2.3. By End User
8. Europe Cancer Gene Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Cancer Gene Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Indication
8.3.1.2.3. By End User
8.3.2. Germany Cancer Gene Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Indication
8.3.2.2.3. By End User
8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Indication
8.3.3.2.3. By End User
8.3.4. Italy Cancer Gene Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Indication
8.3.4.2.3. By End User
8.3.5. Spain Cancer Gene Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Indication
8.3.5.2.3. By End User
9. Asia-Pacific Cancer Gene Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Cancer Gene Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Indication
9.3.1.2.3. By End User
9.3.2. India Cancer Gene Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Indication
9.3.2.2.3. By End User
9.3.3. Japan Cancer Gene Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Indication
9.3.3.2.3. By End User
9.3.4. South Korea Cancer Gene Therapy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Indication
9.3.4.2.3. By End User
9.3.5. Australia Cancer Gene Therapy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Indication
9.3.5.2.3. By End User
10. South America Cancer Gene Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Cancer Gene Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Indication
10.3.1.2.3. By End User
10.3.2. Argentina Cancer Gene Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Indication
10.3.2.2.3. By End User
10.3.3. Colombia Cancer Gene Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Indication
10.3.3.2.3. By End User
11. Middle East and Africa Cancer Gene Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Indication
11.2.3. By End User
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Cancer Gene Therapy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Indication
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Indication
11.3.2.2.3. By End User
11.3.3. UAE Cancer Gene Therapy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Indication
11.3.3.2.3. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Competitive Landscape
14.1. Abeona Therapeutics Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Asklepios BioPharmaceutical Inc.
14.3. Altor Bioscience Inc.
14.4. BioCancell Inc.
14.5. Celgene Inc.
14.6. Elevate Bio Inc.
14.7. Genelux Corporation
14.8. Introgen Therapeutics Inc.
14.9. OncoGenex Pharmaceuticals Inc.
14.10. Merck KGaA
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security